---
title: "Bionano Genomics, Inc. (BNGO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BNGO.US.md"
symbol: "BNGO.US"
name: "Bionano Genomics, Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-21T23:16:16.788Z"
locales:
  - [en](https://longbridge.com/en/quote/BNGO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BNGO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BNGO.US.md)
---

# Bionano Genomics, Inc. (BNGO.US)

## Company Overview

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [bionano.com](https://bionano.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:18.000Z

**Overall: C (0.58)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 40 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.96% |  |
| Net Profit YoY | 62.25% |  |
| P/B Ratio | 0.37 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 13753602.60 |  |
| Revenue | 28738000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -73.78% | E |
| Profit Margin | -109.95% | E |
| Gross Margin | 48.63% | B |
| Revenue YoY | 0.96% | C |
| Net Profit YoY | 62.25% | B |
| Total Assets YoY | -17.36% | E |
| Net Assets YoY | -22.26% | E |
| Cash Flow Margin | 61.07% | C |
| OCF YoY | 0.96% | C |
| Turnover | 0.40 | C |
| Gearing Ratio | 42.19% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Bionano Genomics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.96%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "62.25%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.37",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "13753602.60",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "28738000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-73.78%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-109.95%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "48.63%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "0.96%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "62.25%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-17.36%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-22.26%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "61.07%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.96%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.40",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "42.19%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.44 | 26/59 | - | - | - |
| PB | 0.37 | 3/59 | 0.36 | 0.31 | 0.23 |
| PS (TTM) | 0.48 | 5/59 | 0.60 | 0.48 | 0.40 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-13T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |
| Overweight | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.23 |
| Highest Target | 6.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BNGO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BNGO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BNGO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BNGO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**